Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, Morlet N, Hunyor AP, Essex RW, Arnold JJ, Gillies MC; Fight Retinal Blindness Study Group.

Retina. 2017 Jan 31. doi: 10.1097/IAE.0000000000001496. [Epub ahead of print]

PMID:
28145976
2.

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.

Barthelmes D, Campain A, Nguyen P, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, Guymer R, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness! Project Investigators.

Br J Ophthalmol. 2016 Dec;100(12):1640-1645. doi: 10.1136/bjophthalmol-2015-308090. Epub 2016 Mar 18.

3.

Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study).

Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, Li J, Quin GJ, McAllister IL, Gillies MC.

Ophthalmology. 2016 Jun;123(6):1399-401. doi: 10.1016/j.ophtha.2015.12.012. Epub 2016 Jan 9. No abstract available.

4.

Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial.

Mehta H, Fraser-Bell S, Yeung A, Campain A, Lim LL, Quin GJ, McAllister IL, Keane PA, Gillies MC.

Br J Ophthalmol. 2016 Jul;100(7):1000-1004. doi: 10.1136/bjophthalmol-2015-307797. Epub 2015 Nov 4.

PMID:
26537156
5.

Patient experiences in retinal trials: a cross-sectional study.

Au CP, Fardell N, Williams M, Fraser-Bell S, Campain A, Gillies M.

BMC Ophthalmol. 2015 Jul 23;15:80. doi: 10.1186/s12886-015-0071-6.

6.

Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study.

Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, Essex RW, Morlet N, Hunyor AP; Fight Retinal Blindness Study Group.

Ophthalmology. 2015 Sep;122(9):1837-45. doi: 10.1016/j.ophtha.2015.05.010. Epub 2015 Jun 18.

PMID:
26096346
7.

Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.

Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness Study Group.

Ophthalmology. 2015 Jun;122(6):1212-9. doi: 10.1016/j.ophtha.2015.02.009. Epub 2015 Apr 4.

PMID:
25846847
8.

Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab.

Gillies MC, Campain A, Walton R, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, Hunyor AP, Essex RW, Morlet N, Barthelmes D; Fight Retinal Blindness Study Group.

Ophthalmology. 2015 Mar;122(3):589-594.e1. doi: 10.1016/j.ophtha.2014.10.001. Epub 2014 Nov 6.

PMID:
25458197
9.

Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data.

Barthelmes D, Walton R, Campain AE, Simpson JM, Arnold JJ, McAllister IL, Guymer RH, Hunyor AP, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness! Project Investigators.

Br J Ophthalmol. 2015 Mar;99(3):359-64. doi: 10.1136/bjophthalmol-2014-305514. Epub 2014 Sep 23.

PMID:
25249615
10.

A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.

Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, Goodwin S, Aroney C, McAllister IL, Fraser-Bell S.

Ophthalmology. 2014 Dec;121(12):2473-81. doi: 10.1016/j.ophtha.2014.07.002. Epub 2014 Aug 22.

PMID:
25155371
11.

Intravitreal therapy in bilateral neovascular age-related macular degeneration.

Barthelmes D, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Campain A, Hunyor AP, Guymer R, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness! Project Investigators.

Ophthalmology. 2014 Oct;121(10):2073-4. doi: 10.1016/j.ophtha.2014.05.007. Epub 2014 Jun 14. No abstract available.

PMID:
24939512
12.

Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden.

Schramm SJ, Li SS, Jayaswal V, Fung DC, Campain AE, Pang CN, Scolyer RA, Yang YH, Mann GJ, Wilkins MR.

Pigment Cell Melanoma Res. 2013 Sep;26(5):708-22. doi: 10.1111/pcmr.12126. Epub 2013 Jul 5.

PMID:
23738911
13.

A prediction model for viability at the end of the first trimester after a single early pregnancy evaluation.

Oates J, Casikar I, Campain A, Müller S, Yang J, Reid S, Condous G.

Aust N Z J Obstet Gynaecol. 2013 Feb;53(1):51-7. doi: 10.1111/ajo.12046.

PMID:
23405996
14.

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF, Thompson JF, Yang YH, Scolyer RA.

J Invest Dermatol. 2013 Feb;133(2):509-17. doi: 10.1038/jid.2012.283. Epub 2012 Aug 30.

15.

Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs.

Marques FZ, Campain AE, Tomaszewski M, Zukowska-Szczechowska E, Yang YH, Charchar FJ, Morris BJ.

Hypertension. 2011 Dec;58(6):1093-8. doi: 10.1161/HYPERTENSIONAHA.111.180729. Epub 2011 Oct 31.

16.

Review and cross-validation of gene expression signatures and melanoma prognosis.

Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ.

J Invest Dermatol. 2012 Feb;132(2):274-83. doi: 10.1038/jid.2011.305. Epub 2011 Sep 29. Review.

17.

Genes influencing circadian differences in blood pressure in hypertensive mice.

Marques FZ, Campain AE, Davern PJ, Yang YH, Head GA, Morris BJ.

PLoS One. 2011 Apr 26;6(4):e19203. doi: 10.1371/journal.pone.0019203.

18.

Global identification of the genes and pathways differentially expressed in hypothalamus in early and established neurogenic hypertension.

Marques FZ, Campain AE, Davern PJ, Yang YH, Head GA, Morris BJ.

Physiol Genomics. 2011 Jun 28;43(12):766-71. doi: 10.1152/physiolgenomics.00009.2011. Epub 2011 Apr 12.

19.

Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling.

Loi TH, Campain A, Bryant A, Molloy TJ, Lutherborrow M, Turner J, Yang YH, Ma DD.

BMC Med Genomics. 2011 Mar 31;4:27. doi: 10.1186/1755-8794-4-27.

20.

Compliance in a school-based caries clinical trial of a sugar-free chewing gum.

Bailey DL, Campain AC, Tsao CE, Adams GG, Thomson WJ, Morgan MV.

Contemp Clin Trials. 2011 Jul;32(4):492-7. doi: 10.1016/j.cct.2011.03.003. Epub 2011 Mar 5.

PMID:
21382514

Supplemental Content

Loading ...
Support Center